secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2024-10-25T23:59:59+00:00
Accession:  0001193125-24-244201
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia Phase 2 NTLA-2002: 8/11 patients attack-free after single dose; 77% attack reduction vs placebo
--------------------------------------------------------------------------------

- Mean monthly attack rate reduced by 77% (50 mg) vs placebo during weeks 1-16; 81% during weeks 5-16.
- Eight of 11 patients in 50 mg arm had zero attacks over 16 weeks and remained attack-free through median 8-month follow-up.
- Kallikrein protein reduction: 86% mean reduction from baseline at week 16 (50 mg) vs 55% (25 mg).
- Well-tolerated; no serious AEs in NTLA-2002 arms; most common AEs were headache, fatigue, nasopharyngitis.
- 50 mg dose selected for global Phase 3 HAELO study, which is actively screening patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312524244201/0001193125-24-244201-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312524244201/d842130d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-244201

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer